Aligos Therapeutics, Inc.
ALGS
$7.39
-$0.26-3.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.83M | 169.00K | 741.00K | 965.00K | 311.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.83M | 169.00K | 741.00K | 965.00K | 311.00K |
| Cost of Revenue | 666.00K | 17.04M | 23.94M | 13.98M | 543.00K |
| Gross Profit | 2.16M | -16.87M | -23.20M | -13.01M | -232.00K |
| SG&A Expenses | 6.41M | 4.95M | 5.17M | 5.56M | 5.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.76M | 21.98M | 29.10M | 19.53M | 19.55M |
| Operating Income | -26.93M | -21.81M | -28.36M | -18.57M | -19.24M |
| Income Before Tax | -22.72M | -19.85M | -31.48M | -15.68M | 43.13M |
| Income Tax Expenses | 317.00K | 30.00K | 56.00K | 185.00K | 43.00K |
| Earnings from Continuing Operations | -23.04M | -19.88M | -31.54M | -15.86M | 43.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.04M | -19.88M | -31.54M | -15.86M | 43.09M |
| EBIT | -26.93M | -21.81M | -28.36M | -18.57M | -19.24M |
| EBITDA | -26.58M | -21.56M | -28.14M | -18.31M | -19.05M |
| EPS Basic | -2.21 | -1.91 | -3.04 | -1.53 | 5.12 |
| Normalized Basic EPS | -1.37 | -1.19 | -1.90 | -0.95 | 3.21 |
| EPS Diluted | -2.21 | -1.92 | -3.04 | -1.53 | -2.11 |
| Normalized Diluted EPS | -1.37 | -1.19 | -1.90 | -0.95 | 3.10 |
| Average Basic Shares Outstanding | 10.40M | 10.38M | 10.37M | 10.35M | 8.41M |
| Average Diluted Shares Outstanding | 10.40M | 10.38M | 10.37M | 10.35M | 8.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |